Skip to main content
Top
Published in: Respiratory Research 1/2023

Open Access 01-12-2023 | Septicemia | Research

SLC38A6 expression in macrophages exacerbates pulmonary inflammation

Authors: Yizhao Peng, Weichao Chen, Fumeng Huang, Manman Geng, Xiaowei Li, Fujun Zhang, Wenhua Zhu, Liesu Meng, Rikard Holmdahl, Jing Xu, Shemin Lu

Published in: Respiratory Research | Issue 1/2023

Login to get access

Abstract

Pulmonary inflammation involves complex changes of the immune cells, in which macrophages play important roles and their function might be influenced by metabolism. Slc38a6 acts as a carrier of nutrient for macrophages (Mφ) to exert the function. In this study, pneumonia patient blood was found up-regulated SLC38A6 expression, which correlated with monocytes number and white blood cell number. The similar result was also shown in LPS induced sepsis mice. To reveal the key role of Slc38a6, we used systemic and conditional knock-out mice. Either systemic or LyzCRE specific knock-out could alleviate the severity of sepsis mice, reduce the proinflammatory cytokine TNF-α and IL-1β expression in serum and decrease the monocytes number in bronchial alveolar lavage and peritoneal lavage via flow cytometry. In order to reveal the signal of up-regulated Slc38a6, the Tlr4 signal inhibitor TAK242 and TLR4 knock-out mice were used. By blocking Tlr4 signal in macrophages via TAK242, the expression of Slc38a6 was down-regulated synchronously, and the same results were also found in Tlr4 knock-out macrophages. However, in the overexpressed Slc38a6 macrophages, blocking Tlr4 signal via TAK242, 20% of the mRNA expression of IL-1β still could be expressed, indicating that up-regulated Slc38a6 participates in IL-1β expression process. Collectively, it is the first time showed that an amino acid transporter SLC38A6 up-regulated in monocytes/macrophages promotes activation in pulmonary inflammation. SLC38A6 might be a promising target molecule for pulmonary inflammation treatment.
Appendix
Available only for authorised users
Literature
2.
go back to reference Cilloniz C, et al. Microbial etiology of pneumonia: epidemiology, diagnosis and resistance patterns. Int J Mol Sci. 2016;17(12):2120.CrossRef Cilloniz C, et al. Microbial etiology of pneumonia: epidemiology, diagnosis and resistance patterns. Int J Mol Sci. 2016;17(12):2120.CrossRef
3.
go back to reference Ramirez JA, et al. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis. 2017;65(11):1806–12.CrossRef Ramirez JA, et al. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis. 2017;65(11):1806–12.CrossRef
4.
go back to reference Rubenfeld GD, et al. Incidence and outcomes of acute lung injury. N Engl J Med. 2005;353(16):1685–93.CrossRef Rubenfeld GD, et al. Incidence and outcomes of acute lung injury. N Engl J Med. 2005;353(16):1685–93.CrossRef
5.
go back to reference Assefa M. Multi-drug resistant gram-negative bacterial pneumonia: etiology, risk factors, and drug resistance patterns. Pneumonia. 2022;14(1):4.CrossRef Assefa M. Multi-drug resistant gram-negative bacterial pneumonia: etiology, risk factors, and drug resistance patterns. Pneumonia. 2022;14(1):4.CrossRef
6.
go back to reference Kumar V, Chhibber S. Acute lung inflammation in Klebsiella pneumoniae B5055-induced pneumonia and sepsis in BALB/c mice: a comparative study. Inflammation. 2011;34(5):452–62.CrossRef Kumar V, Chhibber S. Acute lung inflammation in Klebsiella pneumoniae B5055-induced pneumonia and sepsis in BALB/c mice: a comparative study. Inflammation. 2011;34(5):452–62.CrossRef
7.
go back to reference van Vught LA, et al. Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis. JAMA. 2016;315(14):1469–79.CrossRef van Vught LA, et al. Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis. JAMA. 2016;315(14):1469–79.CrossRef
8.
go back to reference Ward PA. Acute and chronic inflammation. In: Serhan CN, Gilroy DW, Ward PA, editors. Fundamentals of inflammation. Cambridge: Cambridge University Press; 2010. p. 1–16. Ward PA. Acute and chronic inflammation. In: Serhan CN, Gilroy DW, Ward PA, editors. Fundamentals of inflammation. Cambridge: Cambridge University Press; 2010. p. 1–16.
9.
go back to reference Nanchal R, Truwit J. Recent advances in understanding and treating acute respiratory distress syndrome [version 1; peer review: 2 approved]. F1000Research. 2018;7:1322.CrossRef Nanchal R, Truwit J. Recent advances in understanding and treating acute respiratory distress syndrome [version 1; peer review: 2 approved]. F1000Research. 2018;7:1322.CrossRef
10.
go back to reference Kumar V. Pulmonary innate immune response determines the outcome of inflammation during pneumonia and sepsis-associated acute lung injury. Front Immunol. 2020;11:1722.CrossRef Kumar V. Pulmonary innate immune response determines the outcome of inflammation during pneumonia and sepsis-associated acute lung injury. Front Immunol. 2020;11:1722.CrossRef
11.
go back to reference Viola A, et al. The Metabolic signature of macrophage responses. Front Immunol. 2019;10:1462.CrossRef Viola A, et al. The Metabolic signature of macrophage responses. Front Immunol. 2019;10:1462.CrossRef
12.
go back to reference Bröer S. The SLC38 family of sodium–amino acid co-transporters. Pflügers Arch Eur J Physiol. 2013;466(1):155–72.CrossRef Bröer S. The SLC38 family of sodium–amino acid co-transporters. Pflügers Arch Eur J Physiol. 2013;466(1):155–72.CrossRef
13.
go back to reference Bröer S, Palacín M. The role of amino acid transporters in inherited and acquired diseases. Biochem J. 2011;436(2):193–211.CrossRef Bröer S, Palacín M. The role of amino acid transporters in inherited and acquired diseases. Biochem J. 2011;436(2):193–211.CrossRef
14.
go back to reference Rjm A, Faca B. Multifaceted regulation of the system A transporter Slc38a2 suggests nanoscale regulation of amino acid metabolism and cellular signaling. Neuropharmacology. 2019;161:107789.CrossRef Rjm A, Faca B. Multifaceted regulation of the system A transporter Slc38a2 suggests nanoscale regulation of amino acid metabolism and cellular signaling. Neuropharmacology. 2019;161:107789.CrossRef
15.
go back to reference Marafi D, Fatih JM, Kaiyrzhanov R, Ferla MP, Gijavanekar C, Al-Maraghi A, Liu N, Sites E, Alsaif HS, Al-Owain M, Zakkariah M, El-Anany E, Guliyeva U, Guliyeva S, Gaba C, Haseeb A, Alhashem AM, Danish E, Karageorgou V, Beetz C, Subhi AA, Mullegama SV, Torti E, Sebastin M, Breilyn MS, Duberstein S, Abdel-Hamid MS, Mitani T, Du H, Rosenfeld JA, Jhangiani SN, Akdemir ZC, Gibbs RA, Taylor JC, Fakhro KA, Hunter JV, Pehlivan D, Zaki MS, Gleeson JG, Maroofian R, Houlden H, Posey JE, Sutton VR, Alkuraya FS, Elsea SH, Lupski JR. Biallelic variants in SLC38A3 encoding a glutamine transporter cause epileptic encephalopathy. Brain. 2021;145:909.CrossRef Marafi D, Fatih JM, Kaiyrzhanov R, Ferla MP, Gijavanekar C, Al-Maraghi A, Liu N, Sites E, Alsaif HS, Al-Owain M, Zakkariah M, El-Anany E, Guliyeva U, Guliyeva S, Gaba C, Haseeb A, Alhashem AM, Danish E, Karageorgou V, Beetz C, Subhi AA, Mullegama SV, Torti E, Sebastin M, Breilyn MS, Duberstein S, Abdel-Hamid MS, Mitani T, Du H, Rosenfeld JA, Jhangiani SN, Akdemir ZC, Gibbs RA, Taylor JC, Fakhro KA, Hunter JV, Pehlivan D, Zaki MS, Gleeson JG, Maroofian R, Houlden H, Posey JE, Sutton VR, Alkuraya FS, Elsea SH, Lupski JR. Biallelic variants in SLC38A3 encoding a glutamine transporter cause epileptic encephalopathy. Brain. 2021;145:909.CrossRef
16.
go back to reference Kim J, et al. Amino acid transporter Slc38a5 controls glucagon receptor inhibition-induced pancreatic α cell hyperplasia in mice. Cell Metab. 2017;25(6):1348-1361.e8.CrossRef Kim J, et al. Amino acid transporter Slc38a5 controls glucagon receptor inhibition-induced pancreatic α cell hyperplasia in mice. Cell Metab. 2017;25(6):1348-1361.e8.CrossRef
17.
go back to reference Gandasi NR, et al. Glutamine uptake via SNAT6 and caveolin regulates glutamine-glutamate cycle. Int J Mol Sci. 2021;22(3):1167.CrossRef Gandasi NR, et al. Glutamine uptake via SNAT6 and caveolin regulates glutamine-glutamate cycle. Int J Mol Sci. 2021;22(3):1167.CrossRef
18.
go back to reference Haratake N, et al. Identification of SLC38A7 as a prognostic marker and potential therapeutic target of lung squamous cell carcinoma. Ann Surg. 2021;274(3):500.CrossRef Haratake N, et al. Identification of SLC38A7 as a prognostic marker and potential therapeutic target of lung squamous cell carcinoma. Ann Surg. 2021;274(3):500.CrossRef
19.
go back to reference Wyant GA, et al. mTORC1 activator SLC38A9 Is required to efflux essential amino acids from lysosomes and use protein as a nutrient. Cell. 2017;171(3):642-654.e12.CrossRef Wyant GA, et al. mTORC1 activator SLC38A9 Is required to efflux essential amino acids from lysosomes and use protein as a nutrient. Cell. 2017;171(3):642-654.e12.CrossRef
20.
go back to reference Kirrbach J. Mapping of the human bitopic membrane proteome for self-interacting transmembrane helices. 2013 Kirrbach J. Mapping of the human bitopic membrane proteome for self-interacting transmembrane helices. 2013
21.
go back to reference Wanderley CW, et al. Paclitaxel reduces tumor growth by reprogramming tumor-associated macrophages to an M1 profile in a TLR4-dependent manner. Can Res. 2018;78(20):5891–900.CrossRef Wanderley CW, et al. Paclitaxel reduces tumor growth by reprogramming tumor-associated macrophages to an M1 profile in a TLR4-dependent manner. Can Res. 2018;78(20):5891–900.CrossRef
22.
go back to reference Schappe MS, et al. Chanzyme TRPM7 mediates the Ca2+ influx essential for lipopolysaccharide-induced toll-like receptor 4 endocytosis and macrophage activation. Immunity. 2018;48(1):59-74.e5.CrossRef Schappe MS, et al. Chanzyme TRPM7 mediates the Ca2+ influx essential for lipopolysaccharide-induced toll-like receptor 4 endocytosis and macrophage activation. Immunity. 2018;48(1):59-74.e5.CrossRef
23.
go back to reference Xu J, et al. Construction of conveniently screening pLKO.1-TRC vector tagged with TurboGFP. Appl Biochem Biotechnol. 2017;181(2):699–709.CrossRef Xu J, et al. Construction of conveniently screening pLKO.1-TRC vector tagged with TurboGFP. Appl Biochem Biotechnol. 2017;181(2):699–709.CrossRef
24.
go back to reference Belchamber K, Donnelly LE. Macrophage dysfunction in respiratory disease. Cham: Springer; 2017.CrossRef Belchamber K, Donnelly LE. Macrophage dysfunction in respiratory disease. Cham: Springer; 2017.CrossRef
25.
go back to reference Manfred K, et al. The development and function of lung-resident macrophages and dendritic cells. Nat Immunol. 2015;16(1):36–44.CrossRef Manfred K, et al. The development and function of lung-resident macrophages and dendritic cells. Nat Immunol. 2015;16(1):36–44.CrossRef
26.
go back to reference Müller-Redetzky H, Suttorp N, Witzenrath M. Experimental models of pneumonia-induced sepsis. Drug Discov Today Dis Model. 2012;9(1):e23–32.CrossRef Müller-Redetzky H, Suttorp N, Witzenrath M. Experimental models of pneumonia-induced sepsis. Drug Discov Today Dis Model. 2012;9(1):e23–32.CrossRef
27.
go back to reference Brooks D, et al. Human lipopolysaccharide models provide mechanistic and therapeutic insights into systemic and pulmonary inflammation. Eur Respir J. 2020;56(1):1901298.CrossRef Brooks D, et al. Human lipopolysaccharide models provide mechanistic and therapeutic insights into systemic and pulmonary inflammation. Eur Respir J. 2020;56(1):1901298.CrossRef
28.
go back to reference Ito S, et al. GADD34 suppresses lipopolysaccharide-induced sepsis and tissue injury through the regulation of macrophage activation. Cell Death Dis. 2016;7(5):e2219–e2219.CrossRef Ito S, et al. GADD34 suppresses lipopolysaccharide-induced sepsis and tissue injury through the regulation of macrophage activation. Cell Death Dis. 2016;7(5):e2219–e2219.CrossRef
29.
go back to reference Kinjyo I, et al. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity. 2002;17(5):583–91.CrossRef Kinjyo I, et al. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity. 2002;17(5):583–91.CrossRef
30.
go back to reference Voss OH, et al. Lipopolysaccharide-induced CD300b receptor binding to toll-like receptor 4 alters signaling to drive cytokine responses that enhance septic shock. Immunity. 2016;44(6):1365–78.CrossRef Voss OH, et al. Lipopolysaccharide-induced CD300b receptor binding to toll-like receptor 4 alters signaling to drive cytokine responses that enhance septic shock. Immunity. 2016;44(6):1365–78.CrossRef
31.
go back to reference Dhaliwal K, et al. Monocytes control second-phase neutrophil emigration in established lipopolysaccharide-induced murine lung injury. Am J Respir Crit Care Med. 2012;186(6):514–24.CrossRef Dhaliwal K, et al. Monocytes control second-phase neutrophil emigration in established lipopolysaccharide-induced murine lung injury. Am J Respir Crit Care Med. 2012;186(6):514–24.CrossRef
32.
go back to reference Herold S, Gabrielli NM, Vadász I. Novel concepts of acute lung injury and alveolar-capillary barrier dysfunction. Am J Physiol Lung Cell Mol Physiol. 2013;305(10):L665–81.CrossRef Herold S, Gabrielli NM, Vadász I. Novel concepts of acute lung injury and alveolar-capillary barrier dysfunction. Am J Physiol Lung Cell Mol Physiol. 2013;305(10):L665–81.CrossRef
33.
go back to reference Short KR, et al. Pathogenesis of influenza-induced acute respiratory distress syndrome. Lancet Infect Dis. 2014;14(1):57–69.CrossRef Short KR, et al. Pathogenesis of influenza-induced acute respiratory distress syndrome. Lancet Infect Dis. 2014;14(1):57–69.CrossRef
34.
go back to reference Zhuo Y, et al. Treatment with 3,4-dihydroxyphenylethyl alcohol glycoside ameliorates sepsis-induced ALI in mice by reducing inflammation and regulating M1 polarization. Biomed Pharmacother. 2019;116: 109012.CrossRef Zhuo Y, et al. Treatment with 3,4-dihydroxyphenylethyl alcohol glycoside ameliorates sepsis-induced ALI in mice by reducing inflammation and regulating M1 polarization. Biomed Pharmacother. 2019;116: 109012.CrossRef
35.
go back to reference Castro P, et al. Inhibition of interleukin-1β reduces mouse lung inflammation induced by exposure to cigarette smoke. Eur J Pharmacol. 2004;498(1):279–86.CrossRef Castro P, et al. Inhibition of interleukin-1β reduces mouse lung inflammation induced by exposure to cigarette smoke. Eur J Pharmacol. 2004;498(1):279–86.CrossRef
36.
go back to reference Wang Z, et al. Solute carrier family 37 member 2 (SLC37A2) negatively regulates murine macrophage inflammation by controlling glycolysis. iScience. 2020;23(5):101125.CrossRef Wang Z, et al. Solute carrier family 37 member 2 (SLC37A2) negatively regulates murine macrophage inflammation by controlling glycolysis. iScience. 2020;23(5):101125.CrossRef
37.
go back to reference Liu PS, et al. α-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. Nat Immunol. 2017;18(9):985–94.CrossRef Liu PS, et al. α-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. Nat Immunol. 2017;18(9):985–94.CrossRef
38.
go back to reference Bottazzi B, Riboli E, Mantovani A. Aging, inflammation and cancer. Semin Immunol. 2018;40:74–82.CrossRef Bottazzi B, Riboli E, Mantovani A. Aging, inflammation and cancer. Semin Immunol. 2018;40:74–82.CrossRef
39.
go back to reference Mantovani A, et al. Interleukin-1 and related cytokines in the regulation of inflammation and immunity. Immunity. 2019;50(4):778–95.CrossRef Mantovani A, et al. Interleukin-1 and related cytokines in the regulation of inflammation and immunity. Immunity. 2019;50(4):778–95.CrossRef
40.
go back to reference Locati M, Mantovani A, Sica A. Macrophage activation and polarization as an adaptive component of innate immunity. Adv Immunol. 2013;120:163–84.CrossRef Locati M, Mantovani A, Sica A. Macrophage activation and polarization as an adaptive component of innate immunity. Adv Immunol. 2013;120:163–84.CrossRef
Metadata
Title
SLC38A6 expression in macrophages exacerbates pulmonary inflammation
Authors
Yizhao Peng
Weichao Chen
Fumeng Huang
Manman Geng
Xiaowei Li
Fujun Zhang
Wenhua Zhu
Liesu Meng
Rikard Holmdahl
Jing Xu
Shemin Lu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2023
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-023-02330-8

Other articles of this Issue 1/2023

Respiratory Research 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine